↓ Skip to main content

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems

Overview of attention for article published in BMC Infectious Diseases, August 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)

Mentioned by

26 tweeters


32 Dimensions

Readers on

101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Published in
BMC Infectious Diseases, August 2016
DOI 10.1186/s12879-016-1770-1
Pubmed ID

Takahiko Fukuchi, Kentaro Iwata, Saori Kobayashi, Tatsuya Nakamura, Goh Ohji


ESBL (Extended spectrum beta-lactamase) producing enterobacteriaceae are challenging organisms with little treatment options. Carbapenems are frequently used, but the emergence of carbapenem resistant enterobacteriaceae is a concerning issue, which may hinder the use of carbapenems. Although cephamycins such as cefoxitin, cefmetazole or cefotetan are effective against ESBL-producers in vitro, there are few clinical data demonstrating effects against bacteremia caused by these organisms. We performed a retrospective observational study on cases of bacteremia caused by ESBL-producers to investigate the efficacy of cefmetazole compared with carbapenems. We also evaluated whether the trend of antibiotic choice changed over years. Sixty-nine patients (male 34, age 69.2 ± 14.4), including two relapse cases, were reviewed for this analysis. The most common causative organisms were Escherichia coli (64, 93 %), followed by Klebsiella pneumoniae and K. oxytoca (2 each, 4 %). The group that received carbapenem therapy (43, 62 %) had increased severity in the Pittsburgh Bacteremic score than the group that received cefmetazole therapy, (1.5 ± 1.5 vs 2.5 ± 2.1, p = 0.048), while analysis of other factors didn't reveal any statistical differences. Five patients in the carbapenem group and one patient in the cefmetazole group died during the observation period (p = 0.24). CTX-M-9 were predominant in this series (59 %). Infectious disease physicians initially recommended carbapenems at the beginning of the current research period, which gradually changed over time favoring the use of cefmetazole instead (p = 0.002). Cefmetazole may be safely given to patients with bacteremia caused by ESBL-producers as a definitive therapy, if one can select out relatively stable patients.

Twitter Demographics

The data shown below were collected from the profiles of 26 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
Unknown 100 99%

Demographic breakdown

Readers by professional status Count As %
Other 29 29%
Researcher 16 16%
Student > Ph. D. Student 7 7%
Student > Master 6 6%
Student > Postgraduate 6 6%
Other 14 14%
Unknown 23 23%
Readers by discipline Count As %
Medicine and Dentistry 50 50%
Immunology and Microbiology 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Agricultural and Biological Sciences 3 3%
Business, Management and Accounting 2 2%
Other 7 7%
Unknown 29 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2018.
All research outputs
of 19,268,016 outputs
Outputs from BMC Infectious Diseases
of 6,741 outputs
Outputs of similar age
of 275,232 outputs
Outputs of similar age from BMC Infectious Diseases
of 1 outputs
Altmetric has tracked 19,268,016 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,741 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,232 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them